Substituted 1,3-thiazole compounds, their production and use
申请人:——
公开号:US20040053973A1
公开(公告)日:2004-03-18
(1) A 1,3-thiazole compound of which the 5-position is substituted with a 4-pyridyl group having a substituent including no aromatic group or (2) a 1,3-thiazole compound of which the 5-position is substituted with a pyridyl group having at the position adjacent to a nitrogen atom of the pyridyl group a substituent including no aromatic group has an excellent p38 MAP kinase inhibitory activity.
The present invention relates to an agent for the prophylaxis or treatment of pain, an agent for suppressing activation of osteoclast, and an inhibitor of osteoclast formation, which contains a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor.
Hematopoietic progenitor kinase 1 (HPK1) is an important negative regulator in T-cell receptor signaling and as a promising key target for immunotherapy. Herein, based on the reported HPK1 inhibitor 2 featuring an isofuranone component, a structural optimization approach was conducted leading to several series of derivatives characterized by containing an isoindoline structural motif. Compound 49 was
造血祖细胞激酶 1 (HPK1) 是 T 细胞受体信号传导的重要负调节因子,也是免疫治疗的一个有前景的关键靶标。在此,基于已报道的具有异呋喃酮成分的HPK1抑制剂2 ,进行了结构优化方法,得到了多个系列以含有异吲哚啉结构基序为特征的衍生物。化合物49被鉴定为一种新的有效 HPK1 抑制剂,IC 50值为 0.9 nM,比化合物2 (5.5 nM) 更有效。它还具有改善的大鼠 IV 曲线和增强的水溶性。它有效抑制 pSLP76 并重振 T 细胞受体 (TCR) 信号传导,促进幼稚 T 细胞和抗原特异性 T 细胞中的 T 细胞功能和细胞因子产生。此外,化合物49逆转了肿瘤微环境 (TME) 中经典免疫抑制因子介导的对 T 细胞活性的抑制。在小鼠 CT-26 肿瘤模型中,该化合物可重振 T 细胞,并在耐受性良好的剂量下协同增强抗 PD1 的抗肿瘤功效。